Relmada Therapeutics (RLMD) Peer Comparison

$3.39

$0.22 (6.94%)

As on 09-Oct-2026 16:00EDT

Market cap

$362 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

2

Div. Yield

0 %

Edit

	Relmada Therapeutics (RLMD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	362	17,083	15,084	14,832	12,532
Revenue ($ Mln)	--	2,782	1,054	2,436	1,664
Net Profit ($ Mln)	-61.93	491.50	755.85	860.62	413.60
Net Margin (%)	--	17.67	71.69	35.33	24.86
RoE (%)	-42.26	110.09	--	42.98	430.03
Price to Earnings	--	35.94	17.57	18.88	32.29
Price-To-Book	1.95	39.70	8.91	7.82	88.91

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Relmada Therapeutics (RLMD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Operating Revenue	0.00	2,782.29	1,054.37	2,435.92	1,663.74
Cost of Revenue	0.00	1,982.07	103.47	85.67	292.42
Gross Profit	--	760.62	588.53	2,236.43	1,167.84
Operating Expenses	65.13	216.81	841.45	1,378.74	440.53
Operating Profit (EBIT)	-65.13	583.40	109.45	971.51	930.79
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-61.93	598.92	101.11	1,035.47	583.34
Provision for Tax	0.00	107.42	-654.74	174.84	169.74
Profit after Tax (Net Income)	-61.93	491.50	755.85	860.62	413.60
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Relmada Therapeutics (RLMD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Shareholder's Funds	206.56	433.86	1,435.90	1,843.76	143.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	5.08	187.89	384.48	288.55	2,089.43
Current Liabilities	7.42	1,435.43	464.70	361.93	344.44
Total Liabilities	94.00	1,975.47	1,302.02	2,844.42	2,525.32

Assets ($ Mln)

	Relmada Therapeutics (RLMD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Non-Current Assets	0.02	1,006.90	895.24	1,243.41	1,644.38
Current Assets	219.04	1,050.29	1,389.84	1,250.82	933.02
Total Assets	94.00	1,975.47	1,302.02	2,844.42	2,525.32
Total Debt*	0.00	144.11	449.89	165.93	2,146.65
Net Current Assets	211.62	-385.14	925.52	888.90	588.59

Cashflow ($ Mln)

	Relmada Therapeutics (RLMD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-45.79	713.22	51.77	884.27	651.56
Cash Flow from Investing Activities	-48.14	-31.14	-8.15	350.44	-545.81
Cash from Financing Activities	93.56	-860.39	34.89	-969.59	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Relmada Therapeutics (RLMD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
ROCE (%)	-94.05	57.43	-30.01	32.82	15.61
ROE (%)	-42.26	110.09	163.18	42.98	430.03
ROA (%)	-49.01	15.64	31.68	29.32	16.19
EBIT Margin (%)	--	21.13	5.73	41.82	36.28
Net Margin (%)	--	17.67	71.69	35.33	24.86
Cash Profit Margin (%)	--	0.00	0.00	0.00	0.00

Growth Ratios

	Relmada Therapeutics (RLMD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	--	24.67	114.85	9.23	41.15
EBIT Growth (%)	-28.71	18.70	136.39	29.37	-14.99
Net Profit Growth (%)	8.68	17.50	378.76	42.89	-25.78
EPS Growth (%)	57.97	26.84	353.27	50.42	-23.48
Book Value Growth (%)	282.52	164.02	816.12	-0.70	-55.81

Valuation Ratios

	Relmada Therapeutics (RLMD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Price / Earnings	-5.74	36.06	-59.76	15.79	24.99
Price / Book Value	1.95	39.70	8.91	7.82	88.91
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	-4.34	27.15	196.34	13.32	20.23
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Relmada Therapeutics (RLMD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debt to Equity	0.00	0.00	0.27	0.00	13.50
Short term debt to equity ratio	0.00	0.06	0.05	0.00	1.46
Current Ratio	29.52	0.73	2.99	3.46	2.71
Quick Ratio	29.52	0.73	2.32	3.38	2.31
Interest Coverage	--	--	1.62	--	29.73

Operating Efficiency Ratios

	Relmada Therapeutics (RLMD)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	--	15.88	21.25	13.74	27.40
Asset Turnover	0.00	0.89	0.44	0.83	0.65
Receivable days	--	50.42	85.52	43.48	98.04
Inventory Days	--	--	1,056.70	96.17	254.12
Payable days	--	6.26	331.01	147.97	24.86
Cash Conversion Cycle	--	--	811.21	-8.32	327.29

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly